Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

May 2, 2023

Study Completion Date

May 2, 2023

Conditions
Prostate Cancer
Interventions
DRUG

89Zr- DFO-MSTP2109A

"If you are enrolled onto Group 1:~Once you are given the diagnostic agent, the following procedures will be done:~PET scans at the approximate times:~* 1-4 hours after the injection~* 24 hours after the injection (the next day, Day 2)~* 48-120 hours after the injection (on either Day 3, 4, or 5)~* 144-168 hours after the injection (on either Day 6, 7, or 8) You will also have research bloods drawn on the following times and days,~* Day 1: before the injection, approximately 5 minutes after, 30 minutes after, 1 hour after and 2-4 hours after the injection.~* At each time of your scheduled PET scan."

DRUG

89Zr DFO-MSTP2109A

"If you are enrolled onto Group 2:~Once you are given the study drug, the following procedures will be done:~You will have one PET scan done. The timing of the PET scan will be determined at the time of your enrollment (\~ 3-7 days after injection).~No research blood work will be drawn in Group 2"

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER